Germany vs Switzerland: Statin use vs. average non-HDL cholesterol levels
Germany
3.4
in 2018
Switzerland
3.4
in 2018
Germany rank
75th
Switzerland rank
75th
Statin use vs. average non-HDL cholesterol levels over time
- Germany
- Switzerland
How they compare
Germany currently reports 3.4 against 3.4 in Switzerland, a difference of 0.
Across all 39 years both countries report, Switzerland has been ahead every year.
Germany ranks 75th and Switzerland ranks 75th of 191 countries.
Switzerland has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Germany | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.4 | 4.67 | 0.27 | Switzerland |
| 1990s | 4.31 | 4.42 | 0.11 | Switzerland |
| 2000s | 3.91 | 3.91 | 0 | — |
| 2010s | 3.56 | 3.56 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Germany or Switzerland?
- Germany, at 3.4 against 3.4 in Switzerland as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Germany and Switzerland?
- 0, with Germany ahead.
- How many years of comparable data are there for Germany and Switzerland?
- 39 years are reported by both, from 1980 to 2018.
- How do Germany and Switzerland rank globally for statin use vs. average non-hdl cholesterol levels?
- Germany ranks 75th and Switzerland ranks 75th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.